Home › Phases › Approved

Approved (57 companies)

Companies with at least one active program at Approved.

Ticker	Company	Therapeutic areas	Approved programs	Lead stage	Mkt cap	Programs
ADCT	ADC Therapeutics	Oncology	1	Approved	$202M	5
ADMA	Adma Biologics	ImmunologyInfectious Disease Rare	3	Approved	$2.82B	4
AGIO	Agios Pharmaceuticals	HematologyMetabolic Rare	3	Approved	$1.76B	7
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	3	Approved	$111M	10
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	2	Approved	$1.39B	9
ARDX	Ardelyx	GI/HepatologyRenal	2	Approved	$724M	4
ARVN	Arvinas	NeurologyOncology Rare	1	Approved	$420M	10
AUTL	Autolus Therapeutics	HematologyImmunology+3 Rare	1	Approved	$341M	12
AXSM	Axsome Therapeutics	Neurology Rare	4	Approved	$6.96B	15
BCRX	Biocryst Pharmaceuticals	DermatologyImmunology+1 Rare	2	Approved	$1.98B	4
CHRS	Coherus Oncology	Oncology	1	Approved	$119M	4
CRNX	Crinetics Pharmaceuticals	MetabolicOncology Rare	1	Approved	—	6
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	1	Approved	$320M	7
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+3 Rare	10	Approved	$1.63B	17
EXEL	Exelixis	CardiovascularOncology	6	Approved	$17.0B	23
FBIO	Fortress Biotech	DermatologyHematology+3 Rare	5	Approved	$61.7M	12
GERN	Geron	Oncology	1	Approved	$638M	3
HRMY	Harmony Biosciences	MetabolicNeurology Rare	4	Approved	$1.94B	17
HROW	Harrow	Ophthalmology Rare	9	Approved	$1.01B	15
IBRX	ImmunityBio	Infectious DiseaseOncology	1	Approved	$9.15B	16
IMCR	Immunocore	DermatologyInfectious Disease+2	2	Approved	$1.60B	15
INSM	Insmed	CardiovascularImmunology+3 Rare	5	Approved	$25.1B	15
IVVD	Invivyd	Infectious Disease	1	Approved	$166M	5
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	13	Approved	$6.55B	29
KURA	Kura Oncology	MetabolicOncology	1	Approved	$647M	12
LEGN	Legend Biotech	Oncology Rare	1	Approved	$4.55B	17
LENZ	LENZ Therapeutics	Ophthalmology	1	Approved	$110M	1
LQDA	Liquidia	CardiovascularImmunology+1 Rare	3	Approved	$3.97B	9
MESO	Mesoblast	CardiovascularGI/Hepatology+2 Rare	1	Approved	$1.85B	5
MIST	Milestone Pharmaceuticals	Cardiovascular	1	Approved	$95.0M	2
NRXP	NRX Pharmaceuticals	Neurology Rare	1	Approved	$103M	7
OMER	Omeros	HematologyNeurology+2 Rare	1	Approved	$1.22B	6
IRD	Opus Genetics	Ophthalmology Rare	2	Approved	$348M	12
OTLK	Outlook Therapeutics	Ophthalmology	1	Approved	$106M	3
PTGX	Protagonist Therapeutics	DermatologyHematology+2 Rare	2	Approved	$8.62B	12
RLAY	Relay Therapeutics	DermatologyOncology Rare	1	Approved	$4.11B	4
REPL	Replimune Group	Oncology	1	Approved	$2.05B	5
RVMD	Revolution Medicines	Oncology	1	Approved	$41.6B	11
RYTM	Rhythm Pharmaceuticals	Metabolic Rare	4	Approved	$7.78B	14
RCKT	Rocket Pharmaceuticals	CardiovascularImmunology Rare	1	Approved	$262M	4
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	4	Approved	$1.91B	11
SCYX	Scynexis	Infectious DiseaseRenal Rare	1	Approved	$34.8M	5
SNDX	Syndax Pharmaceuticals	ImmunologyOncology Rare	3	Approved	$852M	7
TLX	Telix Pharmaceuticals	Oncology	4	Approved	$3.27B	25
TGTX	Tg Therapeutics	Neurology Rare	1	Approved	$9.16B	6
TVTX	Travere Therapeutics	MetabolicRenal Rare	3	Approved	$4.76B	7
RARE	Ultragenyx Pharmaceutical	CardiovascularMetabolic+1 Rare	7	Approved	$1.57B	10
QURE	uniQure	HematologyMetabolic+1 Rare	1	Approved	$1.52B	4
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	8	Approved	$231M	27
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	1	Approved	$2.15B	6
VSTM	Verastem	Oncology	1	Approved	$1.06B	5
VRCA	Verrica Pharmaceuticals	DermatologyOncology	1	Approved	$54.8M	3
VRDN	Viridian Therapeutics	ImmunologyOphthalmology	1	Approved	$3.24B	7
XFOR	X4 Pharmaceuticals	—	1	Approved	$325M	2
XNCR	Xencor	ImmunologyNeurology+1 Rare	2	Approved	$2.68B	28
XERS	Xeris Biopharma	MetabolicNeurology Rare	3	Approved	$2.78B	4
ZYME	Zymeworks	OncologyRespiratory	2	Approved	$2.10B	11